Medscape Hematology-Oncology Headlines 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Supercharge Your Medical Practice With ChatGPT Supercharge Your Medical Practice With ChatGPT
An expert on artificial intelligence in oncology describes why, and how, to integrate ChatGPT into your clinical practice.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity
' This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
The Unknowns of Taxanes for Breast Cancer During Pregnancy The Unknowns of Taxanes for Breast Cancer During Pregnancy
Taxane exposure during pregnancy appears to be safe for mothers and offspring, according to a new retrospective cohort analysis.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
MRD Status Predicts Transplant Benefit in NPM1-Mutated AML MRD Status Predicts Transplant Benefit in NPM1-Mutated AML
MRD-positive patients in first complete remission after induction therapy had a survival benefit after transplant; however, that benefit did not extend to MRD-negative patients after transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Women 50+ May Safely Reduce Mammogram Frequency Post-Surgery Women 50+ May Safely Reduce Mammogram Frequency Post-Surgery
Women aged 50 and older who have undergone curative treatment for breast cancer and remain cancer free after 3 years may safely deescalate mammogram surveillance.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Measurable Residual Disease-Guided Therapy Promising in CLL Measurable Residual Disease-Guided Therapy Promising in CLL
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T
' In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy]. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies
CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Living in a Food Swamp Tied to High Breast Cancer Mortality Living in a Food Swamp Tied to High Breast Cancer Mortality
New research shows higher postmenopausal breast cancer mortality in communities with easier access to unhealthy fast food.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Study Eyes Melanoma Characteristics in AI/AN Population Study Eyes Melanoma Characteristics in AI/AN Population
The primary site with the highest mortality risk was the trunk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2023 Category: Cancer & Oncology Tags: Dermatology Source Type: news
This Test May Guide AML Therapy for Black Pediatric Patients This Test May Guide AML Therapy for Black Pediatric Patients
A new analysis suggests that a polygenic score can help determine the best drug regimens for young Black patients with AML who often face worse outcomes than White patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Can Younger Postmenopausal Women With BC Skip Radiation? Can Younger Postmenopausal Women With BC Skip Radiation?
Women aged 65-70 years old are often offered the option of skipping radiation after lumpectomy for hormone receptor –positive early-stage breast cancer and moving straight to endocrine therapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Combined Rituximab + Omalizumab Promising for Refractory BP Combined Rituximab + Omalizumab Promising for Refractory BP
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration –approved therapies for BP exist.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Dermatology Source Type: news
Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA
If approved, the ADC would join sacituzumab govitecan (Trodelvy, Gilead) as agents that target trophoblast cell-surface antigen-2 (Trop-2), which is universally expressed in breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Patients With HR-Positive Breast Cancer Can Safely Use ART Patients With HR-Positive Breast Cancer Can Safely Use ART
New data from the POSITIVE trial show the efficacy and short-term safety of fertility preservation and assisted reproductive technology (ART) for young women with HR-positive breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
